Intervacc AB (publ) (IVACC.ST)
SEK 0.94
(0.0%)
SEK 0.94
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -68.98 Million SEK | -62.31% |
| 2022 | -57.72 Million SEK | -86.5% |
| 2021 | -23.14 Million SEK | -19.37% |
| 2020 | -19.39 Million SEK | 10.58% |
| 2019 | -21.68 Million SEK | -34.25% |
| 2018 | -16.15 Million SEK | -125.14% |
| 2017 | -7.17 Million SEK | -555.42% |
| 2016 | -785.08 Thousand SEK | -112.88% |
| 2015 | 8.49 Million SEK | -48.29% |
| 2014 | 16.43 Million SEK | 771.08% |
| 2013 | -2.44 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -14.12 Million SEK | -2.28% |
| 2024 Q1 | -13.15 Million SEK | 3.16% |
| 2023 Q1 | -11.27 Million SEK | 33.97% |
| 2023 Q3 | -30.77 Million SEK | -151.35% |
| 2023 Q4 | -15.56 Million SEK | 49.42% |
| 2023 FY | - SEK | -62.31% |
| 2023 Q2 | -12.24 Million SEK | -8.59% |
| 2022 FY | - SEK | -86.5% |
| 2022 Q2 | -9.8 Million SEK | -27.69% |
| 2022 Q1 | -7.67 Million SEK | -6.93% |
| 2022 Q4 | -17.07 Million SEK | -98.28% |
| 2022 Q3 | -8.61 Million SEK | 12.17% |
| 2021 Q2 | -4.58 Million SEK | 6.68% |
| 2021 Q4 | -7.18 Million SEK | -6.01% |
| 2021 FY | - SEK | -19.37% |
| 2021 Q1 | -4.91 Million SEK | 11.16% |
| 2021 Q3 | -6.77 Million SEK | -47.81% |
| 2020 Q3 | -4.86 Million SEK | -14.98% |
| 2020 FY | - SEK | 10.58% |
| 2020 Q2 | -4.23 Million SEK | 11.16% |
| 2020 Q4 | -5.52 Million SEK | -13.58% |
| 2020 Q1 | -4.76 Million SEK | 23.85% |
| 2019 Q4 | -6.25 Million SEK | -33.13% |
| 2019 Q2 | -6.93 Million SEK | -82.96% |
| 2019 Q1 | -3.79 Million SEK | 28.36% |
| 2019 FY | - SEK | -34.25% |
| 2019 Q3 | -4.7 Million SEK | 32.26% |
| 2018 Q2 | -2.32 Million SEK | 41.86% |
| 2018 FY | - SEK | -125.14% |
| 2018 Q4 | -5.29 Million SEK | -16.55% |
| 2018 Q3 | -4.54 Million SEK | -95.45% |
| 2018 Q1 | -3.99 Million SEK | 27.65% |
| 2017 Q4 | -5.52 Million SEK | -528.74% |
| 2017 Q2 | -334.31 Thousand SEK | 23.84% |
| 2017 FY | - SEK | -555.42% |
| 2017 Q1 | -438.93 Thousand SEK | 94.03% |
| 2017 Q3 | -878.47 Thousand SEK | -162.77% |
| 2016 Q2 | 2.13 Million SEK | 261.31% |
| 2016 Q4 | -7.35 Million SEK | -331.48% |
| 2016 FY | - SEK | -112.88% |
| 2016 Q3 | 3.17 Million SEK | 48.77% |
| 2016 Q1 | -1.32 Million SEK | 0.0% |
| 2015 FY | - SEK | -48.29% |
| 2014 FY | - SEK | 771.08% |
| 2013 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 81.245% |
| Camurus AB (publ) | 562.54 Million SEK | 112.262% |
| Mendus AB (publ) | -97.84 Million SEK | 29.501% |
| Lipum AB (publ) | -37.11 Million SEK | -85.835% |
| NextCell Pharma AB | -40.98 Million SEK | -68.305% |
| Simris Alg AB (publ) | -22.36 Million SEK | -208.456% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -303.758% |
| Active Biotech AB (publ) | -43.88 Million SEK | -57.176% |
| Amniotics AB (publ) | -27.14 Million SEK | -154.136% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -385.194% |
| BioArctic AB (publ) | 275.38 Million SEK | 125.048% |
| Cantargia AB (publ) | -284.31 Million SEK | 75.738% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -252.316% |
| CombiGene AB (publ) | -35.33 Million SEK | -95.211% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 51.026% |
| Genovis AB (publ.) | 64.57 Million SEK | 206.826% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 39.969% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -86.312% |
| Kancera AB (publ) | -61.88 Million SEK | -11.458% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -157.551% |
| LIDDS AB (publ) | -39.67 Million SEK | -73.885% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -469.894% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 319.654% |
| OncoZenge AB (publ) | 7.26 Million SEK | 1049.353% |
| Saniona AB (publ) | -69.69 Million SEK | 1.026% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 78.272% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 75.542% |
| Xintela AB (publ) | -53.47 Million SEK | -29.005% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 59.379% |
| Ziccum AB (publ) | -20.34 Million SEK | -239.101% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 3449100.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 70.97% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -3216.346% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -413.588% |
| Corline Biomedical AB | -1.69 Million SEK | -3979.243% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 60.202% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -25.862% |
| Aptahem AB (publ) | -10 Million SEK | -589.164% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 697.281% |
| Fluicell AB (publ) | -25.91 Million SEK | -166.188% |
| Biovica International AB (publ) | -119.5 Million SEK | 42.279% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -63.367% |
| AcouSort AB (publ) | -16.7 Million SEK | -312.98% |
| Abliva AB (publ) | -93.6 Million SEK | 26.31% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 78.383% |
| 2cureX AB (publ) | -35.13 Million SEK | -96.323% |
| I-Tech AB | 30.34 Million SEK | 327.319% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 90.346% |
| Cyxone AB (publ) | -20.41 Million SEK | -237.905% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 32.672% |
| Biosergen AB | 228 Thousand SEK | 30354.386% |
| Nanologica AB (publ) | -62.11 Million SEK | -11.045% |
| SynAct Pharma AB | -222.7 Million SEK | 69.026% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -57.27% |
| BioInvent International AB (publ) | -312.7 Million SEK | 77.941% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 22393.827% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 164342.006% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 70.219% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -682.754% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 36.458% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -501.447% |